Drug intelligence / Profile preview

PL-AC-333

Development stage: Preclinical
Lead developer: Jiangsu ProteLight Pharmaceutical & Biotechnology
Modality: Small Molecules

Overview

PL-AC-333 is a small molecule drug candidate initially developed by Protelight Pharmaceuticals. It is in preclinical development for the treatment of immune system diseases, digestive system disorders, and endocrinology and metabolic diseases. The primary active indications are inflammatory bowel diseases and obesity, with an inactive indication in colorectal cancer. Specific details about its mechanism of action or molecular targets have not been disclosed publicly as of the latest available update[2][3].

Beyond the preview

Go deeper on PL-AC-333.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PL-AC-333.

Explore the full profile